MEDIGENE AG (MDG1.DE) Fundamental Analysis & Valuation

FRA:MDG1 • DE000A40ESG2

Current stock price

0.1335 EUR
-0.05 (-27.64%)
Last:

This MDG1.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. MDG1.DE Profitability Analysis

1.1 Basic Checks

  • MDG1 had negative earnings in the past year.
  • In the past year MDG1 has reported a negative cash flow from operations.
  • MDG1 had negative earnings in each of the past 5 years.
  • In the past 5 years MDG1 reported 4 times negative operating cash flow.
MDG1.DE Yearly Net Income VS EBIT VS OCF VS FCFMDG1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M -20M

1.2 Ratios

  • MDG1 has a Return On Assets of -56.15%. This is in the lower half of the industry: MDG1 underperforms 62.50% of its industry peers.
  • The Return On Equity of MDG1 (-82.28%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -56.15%
ROE -82.28%
ROIC N/A
ROA(3y)-27.97%
ROA(5y)-28.16%
ROE(3y)-40.52%
ROE(5y)-40.06%
ROIC(3y)N/A
ROIC(5y)N/A
MDG1.DE Yearly ROA, ROE, ROICMDG1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60

1.3 Margins

  • MDG1 has a Gross Margin of 72.77%. This is in the better half of the industry: MDG1 outperforms 69.44% of its industry peers.
  • In the last couple of years the Gross Margin of MDG1 has declined.
  • MDG1 does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 72.77%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.13%
GM growth 5Y-3.96%
MDG1.DE Yearly Profit, Operating, Gross MarginsMDG1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. MDG1.DE Health Analysis

2.1 Basic Checks

  • MDG1 does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for MDG1 remains at a similar level compared to 1 year ago.
  • The debt/assets ratio for MDG1 is higher compared to a year ago.
MDG1.DE Yearly Shares OutstandingMDG1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M
MDG1.DE Yearly Total Debt VS Total AssetsMDG1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

  • MDG1 has an Altman-Z score of -25.08. This is a bad value and indicates that MDG1 is not financially healthy and even has some risk of bankruptcy.
  • MDG1 has a worse Altman-Z score (-25.08) than 83.33% of its industry peers.
  • A Debt/Equity ratio of 0.08 indicates that MDG1 is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.08, MDG1 is in the better half of the industry, outperforming 70.83% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Altman-Z -25.08
ROIC/WACCN/A
WACC7.78%
MDG1.DE Yearly LT Debt VS Equity VS FCFMDG1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M 60M 80M 100M

2.3 Liquidity

  • MDG1 has a Current Ratio of 2.39. This indicates that MDG1 is financially healthy and has no problem in meeting its short term obligations.
  • MDG1 has a Current ratio of 2.39. This is comparable to the rest of the industry: MDG1 outperforms 54.17% of its industry peers.
  • MDG1 has a Quick Ratio of 2.39. This indicates that MDG1 is financially healthy and has no problem in meeting its short term obligations.
  • MDG1 has a better Quick ratio (2.39) than 61.11% of its industry peers.
Industry RankSector Rank
Current Ratio 2.39
Quick Ratio 2.39
MDG1.DE Yearly Current Assets VS Current LiabilitesMDG1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. MDG1.DE Growth Analysis

3.1 Past

  • The earnings per share for MDG1 have decreased strongly by -94.19% in the last year.
  • The Revenue for MDG1 has decreased by -80.69% in the past year. This is quite bad
  • Measured over the past years, MDG1 shows a decrease in Revenue. The Revenue has been decreasing by -4.89% on average per year.
EPS 1Y (TTM)-94.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-91.4%
Revenue 1Y (TTM)-80.69%
Revenue growth 3Y-11.65%
Revenue growth 5Y-4.89%
Sales Q2Q%-6%

3.2 Future

  • Based on estimates for the next years, MDG1 will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.04% on average per year.
  • MDG1 is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 20.49% yearly.
EPS Next Y38.46%
EPS Next 2Y20.82%
EPS Next 3Y18.2%
EPS Next 5Y12.04%
Revenue Next Year100%
Revenue Next 2Y90.69%
Revenue Next 3Y13.3%
Revenue Next 5Y20.49%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MDG1.DE Yearly Revenue VS EstimatesMDG1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 10M 20M 30M
MDG1.DE Yearly EPS VS EstimatesMDG1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -0.5 -1 -1.5 -2

More info and screens

Find the best growth stocksShow best growing peers

0

4. MDG1.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • MDG1 reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MDG1. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MDG1.DE Price Earnings VS Forward Price EarningsMDG1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MDG1.DE Per share dataMDG1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

  • MDG1's earnings are expected to grow with 18.20% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.82%
EPS Next 3Y18.2%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MDG1.DE Dividend Analysis

5.1 Amount

  • MDG1 does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

MDG1.DE Fundamentals: All Metrics, Ratios and Statistics

MEDIGENE AG

FRA:MDG1 (4/29/2025, 7:00:00 PM)

0.1335

-0.05 (-27.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-24
Earnings (Next)08-12
Inst Owners2.38%
Inst Owner ChangeN/A
Ins Owners3.36%
Ins Owner ChangeN/A
Market Cap1.99M
Revenue(TTM)6.03M
Net Income(TTM)-16.18M
Analysts82.5
Price Target3.88 (2806.37%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)31.03%
PT rev (3m)31.03%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.33
P/FCF N/A
P/OCF N/A
P/B 0.1
P/tB 0.2
EV/EBITDA N/A
EPS(TTM)-1.25
EYN/A
EPS(NY)-0.81
Fwd EYN/A
FCF(TTM)-1.49
FCFYN/A
OCF(TTM)-1.47
OCFYN/A
SpS0.41
BVpS1.32
TBVpS0.66
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -56.15%
ROE -82.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 72.77%
FCFM N/A
ROA(3y)-27.97%
ROA(5y)-28.16%
ROE(3y)-40.52%
ROE(5y)-40.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.13%
GM growth 5Y-3.96%
F-Score1
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 21.34%
Cap/Sales 5.29%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.39
Quick Ratio 2.39
Altman-Z -25.08
F-Score1
WACC7.78%
ROIC/WACCN/A
Cap/Depr(3y)17.88%
Cap/Depr(5y)24.26%
Cap/Sales(3y)5.12%
Cap/Sales(5y)6.87%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-94.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-91.4%
EPS Next Y38.46%
EPS Next 2Y20.82%
EPS Next 3Y18.2%
EPS Next 5Y12.04%
Revenue 1Y (TTM)-80.69%
Revenue growth 3Y-11.65%
Revenue growth 5Y-4.89%
Sales Q2Q%-6%
Revenue Next Year100%
Revenue Next 2Y90.69%
Revenue Next 3Y13.3%
Revenue Next 5Y20.49%
EBIT growth 1Y-85.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year34.4%
EBIT Next 3Y12.36%
EBIT Next 5Y9.43%
FCF growth 1Y-262.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-257.03%
OCF growth 3YN/A
OCF growth 5YN/A

MEDIGENE AG / MDG1.DE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of MEDIGENE AG (MDG1.DE) stock?

ChartMill assigns a fundamental rating of 2 / 10 to MDG1.DE.


What is the valuation status for MDG1 stock?

ChartMill assigns a valuation rating of 0 / 10 to MEDIGENE AG (MDG1.DE). This can be considered as Overvalued.


How profitable is MEDIGENE AG (MDG1.DE) stock?

MEDIGENE AG (MDG1.DE) has a profitability rating of 1 / 10.


Can you provide the financial health for MDG1 stock?

The financial health rating of MEDIGENE AG (MDG1.DE) is 4 / 10.


Can you provide the expected EPS growth for MDG1 stock?

The Earnings per Share (EPS) of MEDIGENE AG (MDG1.DE) is expected to grow by 38.46% in the next year.